IDH1 - Comprehensive Cross-Database Identifier and Functional Mapping Reference
Section 1: Gene Identifiers
Primary Gene Identifiers
| Database | Identifier | Status |
|---|
| HGNC ID | HGNC:5382 | Approved |
| Approved Symbol | IDH1 | Current |
| Approved Name | isocitrate dehydrogenase (NADP(+)) 1 | Current |
| Ensembl Gene | ENSG00000138413 | Primary |
| NCBI Entrez Gene | 3417 | Primary |
| OMIM | 147700 | Gene/Locus |
Gene Aliases and Previous Names
- Synonyms: HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC, PICD
- Previous Names:
- isocitrate dehydrogenase 1 (NADP+), soluble
- isocitrate dehydrogenase 1 (NADP+)
- isocitrate dehydrogenase (NADP(+)) 1, cytosolic
Genomic Location
| Attribute | Value |
|---|
| Chromosome | 2 |
| Cytogenetic Band | 2q34 |
| Start Position | 208,236,224 (GRCh38) |
| End Position | 208,266,095 (GRCh38) |
| Strand | Minus (-) |
| Genomic Span | ~29.9 kb |
| Genomic Accession | NC_000002.12 |
Gene Classification
- Locus Type: gene with protein product
- Locus Group: protein-coding gene
- Gene Group: Isocitrate dehydrogenases
Section 2: Transcript Identifiers
Ensembl Transcripts
Total Transcript Count: 34
| Transcript ID | Biotype | Start | End | Strand |
|---|
| ENST00000345146 | protein_coding | 208,236,229 | 208,255,071 | - |
| ENST00000415282 | protein_coding | 208,245,367 | 208,254,339 | - |
| ENST00000415913 | protein_coding | 208,236,265 | 208,254,322 | - |
| ENST00000417583 | protein_coding | 208,248,562 | 208,255,798 | - |
| ENST00000446179 | protein_coding | 208,236,232 | 208,254,458 | - |
| ENST00000451391 | protein_coding | 208,248,597 | 208,266,074 | - |
| ENST00000462386 | retained_intron | 208,247,382 | 208,255,061 | - |
| ENST00000481557 | retained_intron | 208,251,261 | 208,255,113 | - |
| ENST00000484575 | retained_intron | 208,236,742 | 208,240,315 | - |
| ENST00000862219 | protein_coding | 208,236,230 | 208,266,042 | - |
| ENST00000862220 | protein_coding | 208,236,230 | 208,255,130 | - |
| ENST00000862221 | protein_coding | 208,236,227 | 208,255,122 | - |
| ENST00000862222 | protein_coding | 208,236,227 | 208,255,071 | - |
| ENST00000862223 | protein_coding | 208,236,230 | 208,255,071 | - |
| ENST00000862224 | protein_coding | 208,236,267 | 208,255,071 | - |
| ENST00000862225 | protein_coding | 208,236,228 | 208,254,368 | - |
| ENST00000862226 | protein_coding | 208,236,227 | 208,254,351 | - |
| ENST00000862227 | protein_coding | 208,236,227 | 208,254,243 | - |
| ENST00000862228 | protein_coding | 208,236,227 | 208,254,242 | - |
| ENST00000862229 | protein_coding | 208,236,227 | 208,254,240 | - |
| ENST00000862230 | protein_coding | 208,236,230 | 208,254,159 | - |
| ENST00000911595 | protein_coding | 208,236,227 | 208,266,095 | - |
| ENST00000911596 | protein_coding | 208,236,230 | 208,255,107 | - |
| ENST00000911597 | protein_coding | 208,236,227 | 208,255,086 | - |
| ENST00000911598 | protein_coding | 208,236,229 | 208,255,071 | - |
| ENST00000911599 | protein_coding | 208,236,229 | 208,255,071 | - |
| ENST00000911600 | protein_coding | 208,236,229 | 208,255,070 | - |
| ENST00000911601 | protein_coding | 208,236,232 | 208,255,071 | - |
| ENST00000911602 | protein_coding | 208,236,229 | 208,255,021 | - |
| ENST00000911603 | protein_coding | 208,236,343 | 208,255,090 | - |
| ENST00000911604 | protein_coding | 208,236,224 | 208,254,923 | - |
| ENST00000911605 | protein_coding | 208,236,231 | 208,254,319 | - |
| ENST00000961866 | protein_coding | 208,236,232 | 208,254,691 | - |
| ENST00000961867 | protein_coding | 208,236,237 | 208,254,624 | - |
Biotype Summary: 31 protein_coding, 3 retained_intron
RefSeq Transcripts (Human)
| Accession | Type | Status | MANE Select |
|---|
| NM_005896 | mRNA | REVIEWED | ✓ YES |
| NM_001282386 | mRNA | REVIEWED | No |
| NM_001282387 | mRNA | REVIEWED | No |
CCDS Identifier
Canonical Transcript Exons (ENST00000345146)
Total Exon Count: 10
| Exon ID | Start | End | Strand | Length |
|---|
| ENSE00001908890 | 208,254,939 | 208,255,071 | - | 133 bp |
| ENSE00001357891 | 208,253,886 | 208,253,959 | - | 74 bp |
| ENSE00003564564 | 208,251,430 | 208,251,567 | - | 138 bp |
| ENSE00000934687 | 208,248,369 | 208,248,660 | - | 292 bp |
| ENSE00002416886 | 208,245,319 | 208,245,424 | - | 106 bp |
| ENSE00002424476 | 208,243,427 | 208,243,604 | - | 178 bp |
| ENSE00000934684 | 208,241,994 | 208,242,145 | - | 152 bp |
| ENSE00000934683 | 208,239,863 | 208,240,003 | - | 141 bp |
| ENSE00003511233 | 208,239,071 | 208,239,233 | - | 163 bp |
| ENSE00000934681 | 208,236,229 | 208,237,169 | - | 941 bp |
Section 3: Protein Identifiers
UniProt Accessions
Total UniProt Entries: 5
| Accession | Type | Status |
|---|
| O75874 | Canonical | ✓ Reviewed (Swiss-Prot) |
| A0A024R3Y6 | Isoform | Unreviewed |
| C9J4N6 | Isoform | Unreviewed |
| C9JJE5 | Isoform | Unreviewed |
| C9JLU6 | Isoform | Unreviewed |
Canonical Protein Properties (O75874)
| Property | Value |
|---|
| Protein Name | Isocitrate dehydrogenase [NADP] cytoplasmic |
| Alternative Names | Cytosolic NADP-isocitrate dehydrogenase, IDPc, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase |
| Length | 414 amino acids |
| Molecular Mass | 46,659 Da (~46.7 kDa) |
RefSeq Protein Accessions (Human)
| Accession | Status | MANE Select |
|---|
| NP_005887 | REVIEWED | ✓ YES |
| NP_001269315 | REVIEWED | No |
| NP_001269316 | REVIEWED | No |
Protein Domains and Families
Total Domain Annotations: 3
| InterPro ID | Name | Type |
|---|
| IPR004790 | Isocitrate_DH_NADP | Family |
| IPR024084 | IsoPropMal-DH-like_dom | Domain |
| IPR019818 | IsoCit/isopropylmalate_DH_CS | Conserved_site |
Section 4: Structure Identifiers
Experimental Structures
Total PDB Structure Count: 60
| PDB ID | Method | Resolution | Description |
|---|
| 6BKX | X-RAY | 1.65 Å | Wild-type IDH1 with covalent inhibitor (His315) |
| 4UMX | X-RAY | 1.88 Å | IDH1 R132H with compound 1 |
| 8VHB | X-RAY | 1.89 Å | IDH1 R132Q with NADPH and α-ketoglutarate |
| 6BL2 | X-RAY | 1.92 Å | Wild-type IDH1 with covalent inhibitor |
| 1T09 | X-RAY | 2.70 Å | Wild-type with NADP |
| 1T0L | X-RAY | 2.41 Å | Wild-type with NADP, isocitrate, Ca2+ |
| 3INM | X-RAY | 2.10 Å | R132H mutant with NADPH, α-KG, Ca2+ |
| 6U4J | X-RAY | 2.11 Å | R132H with FT-2102 (Olutasidenib) |
| 6VEI | X-RAY | 2.10 Å | R132H with AG-881 (Vorasidenib) |
| 8T7O | X-RAY | 2.05 Å | R132H with AG-120 (Ivosidenib) |
| 5K10 | Cryo-EM | 3.8 Å | Wild-type IDH1 |
| 5K11 | Cryo-EM | 3.8 Å | IDH1 with inhibitor |
| 9YHA | Cryo-EM | 2.69 Å | R132H structure |
| 9YHB | Cryo-EM | 2.85 Å | R132H C269S structure |
Additional 46 structures available (primarily X-ray crystallography)
Method Summary: 56 X-ray diffraction, 4 Cryo-EM
Predicted Structures (AlphaFold)
| Model ID | Sequence Length | Global pLDDT | Fraction Very High Confidence |
|---|
| AF-O75874 | 3,281 | 96.00 | 0.95 (95%) |
Section 5: Cross-Species Orthologs
| Organism | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000025950 | Idh1 | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000015020 | Idh1 | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000025375 | idh1 | protein_coding |
| Fruit fly (D. melanogaster) | FBGN0001248 | Idh | protein_coding |
| Worm (C. elegans) | WBGENE00010317 | - | - |
| Yeast (S. cerevisiae) | No direct ortholog | - | IDH1 is NADP-specific; yeast has NAD-dependent IDH |
Section 6: Clinical Variants & AI Predictions
ClinVar Variant Summary
Total Variant Count: 489
| Classification | Count |
|---|
| Pathogenic | 2 |
| Likely Pathogenic | 2 |
| Pathogenic/Likely Pathogenic | 1 |
| Uncertain Significance (VUS) | ~50+ |
| Likely Benign | ~200+ |
| Benign | ~200+ |
Pathogenic/Likely Pathogenic Variants (TOP 5)
| ClinVar ID | HGVS Notation | Classification | Condition |
|---|
| 156444 | c.395G>A (p.Arg132His) | Pathogenic/Likely pathogenic | Glioma, AML |
| 375889 | c.395G>T (p.Arg132Leu) | Pathogenic | Cancer predisposition |
| 375893 | c.394C>A (p.Arg132Ser) | Pathogenic | Cancer predisposition |
| 1172783 | c.890G>T (p.Cys297Phe) | Likely pathogenic | - |
| 134518 | c.565A>G (p.Ile189Val) | Likely pathogenic | - |
Note: The R132H mutation (p.Arg132His) is the most clinically significant, commonly found in gliomas and AML.
SpliceAI Predictions
Total Splice Variant Predictions: 1,517
TOP 20 High-Impact Splice Variants (Score ≥ 0.95)
| Variant | Effect | Delta Score |
|---|
| 2:208237166:CACA:C | acceptor_gain | 1.00 |
| 2:208237168:CA:C | acceptor_gain | 1.00 |
| 2:208237170:C:CC | acceptor_gain | 1.00 |
| 2:208239068:TA:T | donor_loss | 1.00 |
| 2:208239069:AC:A | donor_gain | 1.00 |
| 2:208239069:ACTT:A | donor_loss | 1.00 |
| 2:208239070:C:CT | donor_gain | 1.00 |
| 2:208237175:G:T | acceptor_gain | 1.00 |
| 2:208237168:CACT:C | acceptor_loss | 0.99 |
| 2:208237169:ACTAA:A | acceptor_loss | 0.99 |
| 2:208237170:C:CA | acceptor_loss | 0.99 |
| 2:208237171:T:A | acceptor_loss | 0.99 |
| 2:208239070:CT:C | donor_gain | 0.99 |
| 2:208237167:ACA:A | acceptor_gain | 0.98 |
| 2:208237165:GCACA:G | acceptor_gain | 0.96 |
| 2:208237166:CACAC:C | acceptor_gain | 0.96 |
AlphaMissense Predictions
Total Missense Predictions: 2,765
TOP 50 Likely Pathogenic Missense Variants (Score ≥ 0.90)
| Position | AA Change | Score | Class |
|---|
| 2:208239100:G:T | D375E | 0.997 | likely_pathogenic |
| 2:208239101:T:G | D375A | 0.997 | likely_pathogenic |
| 2:208239102:C:G | D375H | 0.997 | likely_pathogenic |
| 2:208239101:T:C | D375G | 0.995 | likely_pathogenic |
| 2:208239087:G:A | T394I | 0.995 | likely_pathogenic |
| 2:208239103:C:G | K374N | 0.994 | likely_pathogenic |
| 2:208237134:A:G | F397S | 0.993 | likely_pathogenic |
| 2:208239095:G:T | A377D | 0.993 | likely_pathogenic |
| 2:208239100:G:C | D375E | 0.993 | likely_pathogenic |
| 2:208237098:A:C | L405W | 0.991 | likely_pathogenic |
| 2:208237133:G:C | F397L | 0.991 | likely_pathogenic |
| 2:208239098:A:C | L376W | 0.991 | likely_pathogenic |
| 2:208239102:C:T | D375N | 0.989 | likely_pathogenic |
| 2:208237122:A:G | L401P | 0.988 | likely_pathogenic |
| 2:208239096:C:G | A377P | 0.988 | likely_pathogenic |
| 2:208239101:T:A | D375V | 0.996 | likely_pathogenic |
| 2:208237122:A:T | L401H | 0.984 | likely_pathogenic |
| 2:208239102:C:A | D375Y | 0.984 | likely_pathogenic |
| 2:208239107:G:T | T373N | 0.983 | likely_pathogenic |
| 2:208237143:G:T | T394K | 0.983 | likely_pathogenic |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways
Total Pathway Count: 5
| Pathway ID | Name | Disease Pathway |
|---|
| R-HSA-2978092 | Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate | Yes |
| R-HSA-389542 | NADPH regeneration | No |
| R-HSA-6798695 | Neutrophil degranulation | No |
| R-HSA-9033241 | Peroxisomal protein import | No |
| R-HSA-9818025 | NFE2L2 regulating TCA cycle genes | No |
Gene Ontology Annotations
Total GO Terms: 29
Molecular Function (7 terms)
| GO ID | Term |
|---|
| GO:0004450 | isocitrate dehydrogenase (NADP+) activity |
| GO:0050661 | NADP binding |
| GO:0051287 | NAD binding |
| GO:0000287 | magnesium ion binding |
| GO:0042802 | identical protein binding |
| GO:0042803 | protein homodimerization activity |
| GO:0045296 | cadherin binding |
Biological Process (13 terms)
| GO ID | Term |
|---|
| GO:0006099 | tricarboxylic acid cycle |
| GO:0006097 | glyoxylate cycle |
| GO:0006102 | isocitrate metabolic process |
| GO:0006103 | 2-oxoglutarate metabolic process |
| GO:0006739 | NADP+ metabolic process |
| GO:0006740 | NADPH regeneration |
| GO:0006749 | glutathione metabolic process |
| GO:0006979 | response to oxidative stress |
| GO:0008585 | female gonad development |
| GO:0048545 | response to steroid hormone |
| GO:0060696 | regulation of phospholipid catabolic process |
| GO:0071071 | regulation of phospholipid biosynthetic process |
Cellular Component (9 terms)
| GO ID | Term |
|---|
| GO:0005829 | cytosol |
| GO:0005737 | cytoplasm |
| GO:0005777 | peroxisome |
| GO:0005782 | peroxisomal matrix |
| GO:0005739 | mitochondrion |
| GO:0005576 | extracellular region |
| GO:0070062 | extracellular exosome |
| GO:0034774 | secretory granule lumen |
| GO:1904724 | tertiary granule lumen |
Section 8: Protein Interactions & Molecular Networks
Protein-Protein Interactions
STRING Interactions: 5,207+
IntAct Interactions: 110+
BioGRID Interactions: 143
TOP 50 Highest-Confidence Interactors (STRING)
| UniProt | Gene | Confidence Score |
|---|
| O75874 | IDH1 (self) | 939 |
| P07954 | FH | 939 |
| O75390 | CS | 934 |
| P40926 | MDH2 | 933 |
| P16455 | MGMT | 930 |
| P51553 | IDH3G | 924 |
| P21399 | ACO1 | 918 |
| Q6N021 | NNT | 915 |
| Q99798 | ACO2 | 914 |
| Q8IXJ9 | SUCLG2 | 899 |
| Q8N465 | SUCLG1 | 895 |
| P46100 | ATRX | 887 |
| P60484 | PTEN | 836 |
| P04637 | TP53 | 828 |
| P53396 | ACLY | 820 |
| P36888 | FLT3 | 815 |
| Q9Y6K1 | DNMT3A | 797 |
| P00533 | EGFR | 795 |
| O95479 | G6PD | 793 |
| P50213 | IDH3A | 793 |
Key Direct Interactions (IntAct, High Confidence)
| Interactor | Type | Confidence |
|---|
| IDH1-IDH1 | direct interaction (homodimer) | 0.76 |
| CALM1 | direct interaction | 0.65 |
| BRAF | physical association | 0.55 |
| CALR | physical association | 0.56 |
| DLST | physical association | 0.56 |
| PRKACA | physical association | 0.56 |
| NEK7 | physical association | 0.56 |
Protein Similarity
ESM2 Structural/Embedding Similarity
Total Similar Proteins: 51
| UniProt | Top Similarity | Average Similarity |
|---|
| Q9Z2K8 | 1.0000 | 0.9939 |
| Q9Z2K9 | 1.0000 | 0.9940 |
| P41562 | 0.9999 | 0.9939 |
| P48735 (IDH2) | 0.9999 | 0.9932 |
| P54071 (IDH2) | 0.9999 | 0.9931 |
| O88844 (Mouse Idh1) | 0.9998 | 0.9936 |
| Q6XUZ5 | 0.9998 | 0.9934 |
| P33198 | 0.9987 | 0.9936 |
DIAMOND Sequence Homology
Total Homologous Proteins: 36
| UniProt | Identity | Bit Score | Protein |
|---|
| O75874 | 99.30% | 835 | Self |
| P65098 | 100.00% | 832 | Bacterial IDH |
| Q9Z2K8 | 99.80% | 839 | Mouse Idh1 |
| P48735 | 99.60% | 927 | Human IDH2 |
| P54071 | 98.90% | 924 | Human IDH2 |
| O88844 | 98.10% | 824 | Mouse Idh1 |
| P41562 | 98.60% | 830 | Rat Idh1 |
Section 9: Transcription Factor Regulatory Data
Note: IDH1 is NOT a transcription factor. It is a metabolic enzyme.
Upstream Regulators (TFs that regulate IDH1)
Total Regulatory Interactions: 6
| TF Gene | Regulation | Confidence |
|---|
| SREBF1 | Activation | High |
| SREBF2 | Activation | High |
| FOXO1 | Unknown | - |
| FOXO3 | Unknown | - |
| FOXO4 | Unknown | - |
| FOXO6 | Unknown | - |
Section 10: Drug & Pharmacology Data
Drug Target Information
| ChEMBL Target | Name | Type |
|---|
| CHEMBL2007625 | Isocitrate dehydrogenase [NADP] cytoplasmic | SINGLE PROTEIN |
| CHEMBL4523659 | IDH1/IDH2 | PROTEIN FAMILY |
Total Drug/Compound Molecules Targeting IDH1: 9,130+ bioactivities
FDA-Approved IDH1 Inhibitors (Phase 4)
| ChEMBL ID | Drug Name | Brand Name | Mechanism | ATC Code |
|---|
| CHEMBL3989958 | IVOSIDENIB | Tibsovo | Mutant IDH1 inhibitor | L01XM02 |
| CHEMBL4279047 | VORASIDENIB | Voranigo | IDH1/IDH2 dual inhibitor | L01XM04 |
| CHEMBL4297610 | OLUTASIDENIB | Rezlidhia | Mutant IDH1 inhibitor | L01XM03 |
| CHEMBL3989908 | ENASIDENIB | Idhifa | IDH2 inhibitor (related) | - |
Ivosidenib (AG-120) - Detailed Profile
| Property | Value |
|---|
| ChEMBL ID | CHEMBL3989958 |
| Development Phase | Phase 4 (Approved) |
| Type | Small molecule |
| Alternative Names | AG-120, Tibsovo |
| Chemical Name | (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
Approved Indications:
- Acute Myeloid Leukemia (AML) with IDH1 mutation
- Cholangiocarcinoma with IDH1 mutation
Clinical Trials (Ivosidenib)
Total Clinical Trials: 51
Phase 3 Trials (7)
| Trial ID | Title | Status |
|---|
| NCT02989857 | ClarIDHy - Cholangiocarcinoma | COMPLETED |
| NCT03173248 | Ivosidenib + Azacitidine in AML | ACTIVE_NOT_RECRUITING |
| NCT03839771 | Ivosidenib + Induction/Consolidation in AML | ACTIVE_NOT_RECRUITING |
| NCT05615818 | Personalized Medicine - Biliary Cancer | RECRUITING |
| NCT05876754 | Early Access - Cholangiocarcinoma | RECRUITING |
| NCT06127407 | Chondrosarcoma | RECRUITING |
| NCT06465953 | MDS with IDH1 Mutation | RECRUITING |
Pharmacogenomics
| PharmGKB Gene | - VIP Gene | - CPIC Guideline | - Chromosome |
|---|
| PA29630 | | | |
| Yes (Very Important Pharmacogene) | No | chr2 |
---
Section 11: Expression Profiles
Expression Summary (Bgee)
| Property | Value |
|---|
| Expression Breadth | Ubiquitous |
| Total Present Calls | 294 |
| Total Conditions | 295 |
| Max Expression Score | 99.62 |
| Average Expression Score | 91.13 |
| Gold Quality Calls | 287 |
TOP 30 Expressing Tissues
| Rank | Tissue/Organ | Expression Score | Quality |
|---|
| 1 | Corpus epididymis | 99.62 | Gold |
| 2 | Jejunal mucosa | 99.50 | Gold |
| 3 | Adrenal tissue | 99.47 | Gold |
| 4 | Right adrenal gland cortex | 99.33 | Gold |
| 5 | Right adrenal gland | 99.24 | Gold |
| 6 | Mucosa of sigmoid colon | 99.12 | Gold |
| 7 | Colonic mucosa | 99.07 | Gold |
| 8 | Left adrenal gland | 99.04 | Gold |
| 9 | Adrenal cortex | 99.03 | Gold |
| 10 | Left adrenal gland cortex | 98.94 | Gold |
| 11 | Secondary oocyte | 98.92 | Gold |
| 12 | Duodenum | 98.87 | Gold |
| 13 | Oocyte | 98.74 | Gold |
| 14 | Adrenal gland | 98.72 | Gold |
| 15 | Seminal vesicle | 98.55 | Gold |
| 16 | Caput epididymis | 98.55 | Gold |
| 17 | Mucosa of transverse colon | 98.47 | Gold |
| 18 | Rectum | 98.46 | Gold |
| 19 | Cortical plate | 98.40 | Gold |
| 20 | Pigmented layer of retina | 98.35 | Gold |
| 21 | Liver | 98.32 | Gold |
| 22 | Cauda epididymis | 98.32 | Gold |
| 23 | Esophagus squamous epithelium | 98.26 | Gold |
| 24 | Ganglionic eminence | 98.25 | Gold |
| 25 | Embryo | 98.09 | Gold |
| 26 | Germinal epithelium of ovary | 98.07 | Gold |
| 27 | Mammary duct | 98.05 | Gold |
| 28 | Adult organism | 98.03 | Gold |
| 29 | Mammalian vulva | 97.96 | Gold |
| 30 | Oral cavity | 97.92 | Gold |
Single-Cell Expression Data
Total Single-Cell Datasets: 5
| Accession | Description | Species | Cell Count |
|---|
| E-ANND-5 | Developing human immune system across organs | Homo sapiens | 911,873 |
| E-MTAB-6524 | Human iPSC transcriptomics | Homo sapiens | 10,926 |
| E-MTAB-7052 | Human dermal fibroblasts | Homo sapiens | 1,920 |
| E-MTAB-3929 | Human preimplantation embryos | Homo sapiens | 1,529 |
| E-GEOD-100618 | Human haemopoietic progenitors | Homo sapiens | 415 |
Section 12: Disease Associations
Mendelian/Monogenic Disease Links (Orphanet)
Total Disease Associations: 6
| Orphanet ID | Disease Name | Type | Gene Count |
|---|
| 163634 | Maffucci syndrome | Disease | 2 |
| 296 | Ollier disease | Disease | 3 |
| 99646 | Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria | Disease | 1 |
| 86845 | Acute myeloid leukaemia with myelodysplasia-related features | Disease | 5 |
| 251576 | Gliosarcoma | Histopathological subtype | 12 |
| 251579 | Giant cell glioblastoma | Histopathological subtype | 13 |
GenCC Disease-Gene Validity
| Disease | Classification | Inheritance | Submitter |
|---|
| Maffucci syndrome | Limited | Autosomal dominant | Ambry Genetics |
Phenotype Associations (HPO)
Total Phenotype Terms: 111
TOP 50 Associated Phenotypes
| HPO ID | Phenotype |
|---|
| HP:0000006 | Autosomal dominant inheritance |
| HP:0002664 | Neoplasm |
| HP:0005701 | Multiple enchondromatosis |
| HP:0005868 | Metaphyseal enchondromatosis |
| HP:0006765 | Chondrosarcoma |
| HP:0009592 | Astrocytoma |
| HP:0012174 | Glioblastoma multiforme |
| HP:0002888 | Ependymoma |
| HP:0004820 | Acute myelomonocytic leukemia |
| HP:0012321 | D-2-hydroxyglutaric aciduria |
| HP:0000256 | Macrocephaly |
| HP:0001263 | Global developmental delay |
| HP:0001510 | Growth delay |
| HP:0004322 | Short stature |
| HP:0002650 | Scoliosis |
| HP:0000926 | Platyspondyly |
| HP:0001048 | Cavernous hemangioma |
| HP:0007461 | Hemangiomatosis |
| HP:0002797 | Osteolysis |
| HP:0002757 | Recurrent fractures |
| HP:0002756 | Pathologic fracture |
| HP:0002119 | Ventriculomegaly |
| HP:0012448 | Delayed myelination |
| HP:0007033 | Cerebellar dysplasia |
| HP:0100021 | Cerebral palsy |
GWAS Associations
Total GWAS Associations: 4
| Study ID | Trait | P-value |
|---|
| GCST004348_17 | Non-glioblastoma glioma | 2.00E-10 |
| GCST011004_8 | Adult diffuse glioma (IDH mutation) | 3.00E-08 |
| GCST004347_11 | Glioma | 3.00E-06 |
| GCST006904_9 | Cerebral amyloid deposition (PET imaging) | 5.00E-06 |
Summary Statistics
| Category | Count |
|---|
| Ensembl Transcripts | 34 |
| RefSeq mRNA (Human) | 3 |
| UniProt Entries | 5 |
| PDB Structures | 60 |
| Orthologs | 5 |
| ClinVar Variants | 489 |
| SpliceAI Predictions | 1,517 |
| AlphaMissense Predictions | 2,765 |
| GO Terms | 29 |
| Reactome Pathways | 5 |
| STRING Interactions | 5,207+ |
| HPO Phenotypes | 111 |
| GWAS Associations | 4 |
| Orphanet Diseases | 6 |
| Approved Drugs | 4 |
| Clinical Trials | 51+ |
Reference compiled from: HGNC, Ensembl, NCBI, UniProt, PDB, AlphaFold, ClinVar, AlphaMissense, SpliceAI, Reactome, Gene Ontology, STRING, IntAct, BioGRID, ChEMBL, Bgee, HPO, GWAS Catalog, Orphanet,
GenCC, PharmGKB
I have compiled a comprehensive cross-database identifier and functional mapping reference for human IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic).
This reference covers all 12 requested sections with data gathered from 70+ biological databases including:
Key Highlights:
- Gene: HGNC:5382 | ENSG00000138413 | Entrez 3417 | Chr 2q34 (208,236,224-208,266,095)
- Protein: UniProt O75874 | 414 amino acids | 46.7 kDa
- Structures: 60 PDB entries (including key R132H mutant structures) + AlphaFold (pLDDT 96%)
- Clinical Variants: 489 ClinVar entries (including critical R132H somatic mutation)
- AI Predictions: 1,517 SpliceAI + 2,765 AlphaMissense predictions
- Approved Drugs: 4 FDA-approved IDH inhibitors (Ivosidenib, Vorasidenib, Olutasidenib, Enasidenib)
- Clinical Trials: 51+ trials for Ivosidenib alone
- Disease Links: Maffucci syndrome, Ollier disease, gliomas, AML
- Expression: Ubiquitous (highest in adrenal, liver, reproductive tissues)
The R132H mutation is particularly significant as a driver mutation in gliomas and acute myeloid leukemia, which has led to the development of multiple targeted therapies now in clinical use.